Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.79 |
| ▸ | CD69 | Q07108 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17922225 | 0.89 | BTK (0.79) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17781672 | 0.88 | BTK (1.00) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL29547553 | 0.88 | BTK (1.00) | BTKKCNH2CD69 | |
| SCHEMBL17937552 | 0.88 | BTK (0.81) | BTKKCNH2CD69 | |
| SCHEMBL17937551 | 0.87 | BTK (0.85) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17781705 | 0.86 | BTK (0.95) | BTKKCNH2CD69 | |
| SCHEMBL17937549 | 0.85 | BTK (0.81) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17781505 | 0.84 | BTK (0.91) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17819014 | 0.84 | BTK (0.91) | BTKKCNH2CD69 | |
| Sofnobrutinib SCHEMBL17781553 | 0.84 | BTK (0.91) | BTKKCNH2CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221991-A1 | NOVEL TRIAZINE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20160221991-A1 | NOVEL TRIAZINE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2016-08-04 | — | — | US | disclosed |
| EP-3048102-A1 | NOVEL TRIAZINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2016-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221991-A1 | NOVEL TRIAZINE DERIVATIVE | BAZ2A, BAZ2B, DOT1L | BTK 3033/4885KCNH2 185/4885CD69 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.